Monitor for initial hsCRP inhibition data from the cardiovascular risk cohort by year-end 2026, which would provide the first efficacy signal. Full Phase 1/1b results in H1 2027 are the next major catalyst.
Price Chart
Executive Summary
AC Immune announced positive preliminary Phase 1 data for its wholly-owned NLRP3 inhibitor ACI-19764, showing safety, tolerability, and CSF brain penetration in healthy volunteers. The therapeutic dose is expected at ≤10mg once daily, and a cardiovascular risk cohort is now dosing with initial hsCRP results expected by year-end.
Key Facts
- ACI-19764 was safe and well-tolerated across SAD and MAD cohorts up to 20mg per day (SAD) with no serious adverse events or treatment withdrawals.
- Clear CSF penetration confirmed; daily doses ≤10mg achieved PK concentrations above IC90 with dose-dependent IL-1beta inhibition.
- Phase 1b cardiovascular risk cohort (elevated hsCRP, type 2 diabetes, or obesity) now dosing; initial results expected by year-end 2026.
- Full Phase 1/1b results expected in H1 2027.
- AC Immune has >$4.5 billion in potential milestone payments from pharma partnerships, plus royalties.
Financial Impact
No financial data provided; early-stage clinical program with no revenue or deal value disclosed.
Risk Factors
- Early-stage data with no efficacy proof yet; hsCRP reduction may not translate to clinical benefit.
- NLRP3 inhibitor space is competitive with multiple large pharma programs.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3348200 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 18d ago | 3/A | $2.45 $2.40 | ▼ −2.04% | ▼ −2.03% | $2.25 (−8.16%) |
Oct 9, 2026 18d ago | 3 | $2.50 $2.45 | ▼ −2.00% | ▼ −1.94% | $2.25 (−10.00%) |
Oct 2, 2026 25d ago | 6-K | $2.73 $2.71 | ▼ −0.55% | ▼ −1.22% | $2.25 (−17.43%) |
Sep 23, 2026 4w ago | 6-K | $2.83 $2.66 | ▼ −6.01% | ▼ −5.92% | $2.25 (−20.49%) |
Sep 3, 2026 7w ago | 6-K | $2.93 $2.86 | ▼ −2.39% | ▼ −2.00% | $2.25 (−23.21%) |
Aug 20, 2026 9w ago | 6-K | $2.64 $2.90 | ▲ +9.85% | ▲ +9.44% | $2.25 (−14.77%) |
Aug 20, 2026 9w ago | Press Release | $2.64 $2.90 | ▲ +9.85% | ▲ +9.44% | $2.25 (−14.77%) |
Aug 11, 2026 11w ago | 6-K | $2.54 $2.62 | ▲ +3.15% | ▲ +2.90% | $2.25 (−11.42%) |
Aug 11, 2026 11w ago | Press Release | $2.54 $2.62 | ▲ +3.15% | ▲ +2.90% | $2.25 (−11.42%) |
Aug 5, 2026 11w ago | 6-K | $2.29 $2.32 | ▲ +1.31% | ▲ +1.47% | $2.25 (−1.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers